

Fax cover sheet

To: _____

Fax number: _____

Date/time: _____

From: _____

Fax number: _____

Number of pages (including this one): _____

Comments:

REQUIRED DOCUMENTATION

- 1) Complete patient enrollment
- 2) Document PAH diagnosis
- 3) Determine PAH clinical status
- 4) Complete CCB trial
- 5) Provide required documentation: right heart catheterization, echocardiogram results, and history and physical notes

Reminder: Please include photocopy of both sides of patient insurance card.

Fax completed forms to your patient's specialty pharmacy:

Accredo Specialty Pharmacy

Fax: 1-800-711-3526

Phone: 1-866-344-4874

CVS/specialty

Fax: 1-877-943-1000

Phone: 1-877-242-2738

Submission of the VELETRI enrollment form is not a guarantee of patient approval. Additional testing and clinical information may be requested in some cases, including:

- Antinuclear antibody results
- Pulmonary function tests
- V/Q perfusion scan
- Chest CT

2

Document diagnosis

Fax to your patient's specialty pharmacy:

Accredo Specialty Pharmacy

Fax: 1-800-711-3526

CVS/specialty

Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

It is the responsibility of the Prescriber to complete this form with information that most accurately and completely describes the condition of the patient, regardless of the potential impact on insurance coverage or reimbursement. Actelion makes no representation that the diagnosis information printed on this form is accurate or complete or that it will support insurance coverage or reimbursement.

Please select the diagnosis information that most accurately and completely describes the signs, symptoms, and condition of the patient:

DIAGNOSIS—THE FOLLOWING ICD 10 CODES DO NOT SUGGEST APPROVAL, COVERAGE, OR REIMBURSEMENT FOR SPECIFIC USES OR INDICATIONS. (CHECK THE BOX FOR THE APPROPRIATE CODE BELOW.)

ICD-10 I27.0 Primary pulmonary hypertension

ICD-10 I27.21 Secondary pulmonary arterial hypertension

Other: _____

MEDICAL RATIONALE FOR OTHER

Prescriber signature: _____ Date: _____

3

Determine clinical status

Fax to your patient's specialty pharmacy:

Accredo Specialty Pharmacy CVS/specialty
Fax: 1-800-711-3526 Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

NYHA functional class: (Check only one)

Class III

Class IV

Other: _____

Clinical signs and symptoms: (Check all appropriate)

Fatigue

Shortness of breath or dyspnea on exertion

6-minute walk distance: _____ meters Date of evaluation: _____

Chest pain or pressure (angina)

Syncope or near syncope

Edema or fluid retention

Increasing limitation of physical activity

Other: _____

Course of illness: (Check all appropriate)

Evidence of worsening heart failure (eg, rales on physical exam, worsening edema, increased NT-proBNP, increased CRP)

Worsening pulmonary hemodynamics (eg, mPAP, RAP, PVR, CO)

Decreasing 6-minute walk test

Change in functional class

Worsening dyspnea on exertion

Change in patient-reported symptoms (eg, increased fatigue)

Other: _____

Prescriber signature: _____ **Date:** _____

4

Complete calcium channel blocker trial

Fax to your patient's specialty pharmacy:

Accredo Specialty Pharmacy CVS/specialty
Fax: 1-800-711-3526 Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

Prior to the initiation of VELETRI® (epoprostenol) for Injection, Medicare policy requires documentation that a calcium channel blocker (CCB) has been tried, failed, or considered and ruled out.

The above named patient was trialed as follows:

A CCB was not trialed because:

Patient did not meet ACCP Guidelines for Vasodilator Response (ie, a fall in mPAP ≥ 10 mmHg to ≤ 40 mmHg, with an unchanged or increased cardiac output)

Patient is hemodynamically unstable or has history of postural hypotension

Patient has systemic hypotension (SBP ≤ 90 mmHg)

Patient has depressed cardiac output (cardiac index ≤ 2.4 L/min/m²)

Patient has known hypersensitivity

Patient has documented bradycardia or second- or third-degree heart block

Patient has signs of right-sided heart failure

Other: _____

OR

The following CCB was trialed:

CCB: _____

With the following response:

Pulmonary arterial pressure continued to rise

Disease continued to progress or patient remained symptomatic

Patient hypersensitive or allergic

Adverse event: _____

Patient became hemodynamically unstable

Other: _____

Prescriber signature: _____ **Date:** _____

